Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed FCF Margin for 4 consecutive years, with 154.82% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 20299.0% to 154.82% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 203.14% through Dec 2025, down 21771.0% year-over-year, with the annual reading at 203.14% for FY2025, 21771.0% down from the prior year.
  • FCF Margin hit 154.82% in Q4 2025 for ARS Pharmaceuticals, down from 127.77% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 48.17% in Q4 2024 to a low of 166990.0% in Q2 2023.
  • Historically, FCF Margin has averaged 19903.66% across 4 years, with a median of 877.0% in 2022.
  • Biggest five-year swings in FCF Margin: crashed -16548224bps in 2023 and later skyrocketed 16552660bps in 2024.
  • Year by year, FCF Margin stood at 2983.6% in 2022, then plummeted by -5497bps to 166990.0% in 2023, then soared by 100bps to 48.17% in 2024, then crashed by -421bps to 154.82% in 2025.
  • Business Quant data shows FCF Margin for SPRY at 154.82% in Q4 2025, 127.77% in Q3 2025, and 288.61% in Q2 2025.